Reactivating NK Cells in Treating Refractory Head and Neck Cancer

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2015
This study aims to determine the safety and efficacy of expanded activated autologous NK cells administered after cetuximab in patients with EGFR-positive nasopharyngeal carcinoma or head and neck squamous cell carcinoma.
Epistemonikos ID: 1720330cc9ef8971a65cb6b37ddcbc990fdb27ef
First added on: May 12, 2024